Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1426 to 1440 of 2006 results for nice guidelines

  1. Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]

    Discontinued Reference number: GID-TAG414

    Technology appraisal guidance
    Discontinued

  2. Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)

    Evidence-based recommendations on inclisiran (Leqvio) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.

    Technology appraisal guidance
    Published
    6 October 2021
    View recommendations

    Sections for TA733

  3. Intrapartum care for healthy women and babies (CG190)

    This guideline has been updated and replaced by the NICE guideline on intrapartum care (NG235).

    Withdrawn guideline

  4. COVID-19 rapid guideline: critical care in adults (NG159)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Withdrawn guideline

  5. COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community (NG163)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Withdrawn guideline

  6. COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community (NG165)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Withdrawn guideline

  7. COVID-19 rapid guideline: acute myocardial injury (NG171)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Withdrawn guideline

  8. COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital (NG173)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Withdrawn guideline

  9. COVID-19 rapid guideline: acute kidney injury in hospital (NG175)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Withdrawn guideline

  10. COVID-19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 (ES27)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Withdrawn advice

  11. COVID-19 rapid evidence summary: Tocilizumab for COVID-19 (ES33)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Withdrawn advice

  12. COVID-19 rapid evidence summary: Sarilumab for COVID-19 (ES34)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Withdrawn advice

  13. COVID-19 rapid guideline: reducing the risk of venous thromboembolism in over 16s with COVID-19 (NG186)

    This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.

    Withdrawn guideline

  14. High-sensitivity troponin tests for the early rule out of NSTEMI (HTG552)

    Evidence-based recommendations on high-sensitivity troponin tests for the early rule out of NSTEMI (non-ST-segment elevation myocardial infarction).

    HealthTech guidance
    Published
    26 August 2020
    View recommendations

    Sections for HTG552

  15. Evidence standards framework for digital health technologies (ECD7)

    This document describes an evidence standards framework (ESF) for digital health technologies (DHTs). It was developed by NICE between June 2018 and February 2019 in collaboration with NHS England, Public Health England and MedCity. The work was commissioned by NHS England